Elicera Therapeutics AB Cash Flow Statement

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	-14.99	-17.94	-16.88	-17.1	-19.36	-13.12
Depreciation & Amortization	-	-	0.01	0.01	0.01	0.01
Other Adjustments	0.54	0.54	0.77	0.7	-0.08	-0
Changes in Accounts Payable	-2.98	0.52	1.16	0.15	-1.32	0.1
Changes in Income Taxes Payable	-	-	-	-	0	-
Changes in Other Operating Activities	-8.51	-4.67	-8.53	1.31	12.17	-1.28
Operating Cash Flow	-17.71	-21.55	-23.46	-14.92	-8.57	-13.11
Purchases of Intangible Assets	0	0	-	-0	-	-
Other Investing Activities	-0	-	-	0.48	-	-0
Investing Cash Flow	-	0	-	0.48	-	-0
Issuance of Common Stock	-	22.03	27.56	-	-	55.12
Net Common Stock Issued (Repurchased)	-	22.03	27.56	-	-	55.12
Other Financing Activities	-	-2.03	-7.08	-	-	-
Financing Cash Flow	-	20	20.48	-	-	55.12
Net Cash Flow	-27.79	-1.55	-2.98	-14.49	-8.57	40.83
Free Cash Flow	-17.71	-21.55	-23.46	-14.92	-8.57	-13.11
FCF Margin	-166.52%	-198.53%	-329.16%	-132.88%	-669.50%	-2233160.00%
Free Cash Flow Per Share	-0.36	-0.47	-0.74	-0.76	-0.37	-0.73
Levered Free Cash Flow	-25.94	-21.55	-23.46	-14.92	-8.57	-14.29
Unlevered Free Cash Flow	-26.48	-22.09	-24.24	-15.62	-8.49	-14.29